Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Convergence-sibling Calchan appoints former Pfizer man as CSO

This article was originally published in Scrip

Executive Summary

Calchan, a small UK-based biotech company focused on the R&D of novel molecules targeting pain and inflammation, has appointed Zahid Ali as chief scientific officer. He joins from Pfizer where he was a senior director of clinical research. Calchan was formed at the same time as Convergence Pharmaceuticals (sold to Biogen recently in a deal worth up to $675m), also using ex-GSK assets. Calchan is being run by much of Convergence's old management team using funds that were carved out from money raised by Convergence prior to its sale. Its most advanced project is a Phase I/II asset, CNV2197944, which is a novel state-dependent calcium channel blocker (Cav2.2) with efficacy across a range of preclinical pain models. The company's second program is at a preclinical stage and targets the apoptosis signal-regulating kinase 1 (ASK1) which is implicated in pain, inflammation, ischemia, fibrosis, cancer and neurodegeneration. The program is partnered with Galapagos.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel